Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
INmune Bio, Inc. (INMB) had Return on Equity of -195.26% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$0.05M |
|
$-45.93M |
|
-- |
|
$0.05M |
|
$47.43M |
|
$-47.38M |
|
$1.45M |
|
$-45.93M |
|
$-45.93M |
|
$-45.93M |
|
$-45.93M |
|
$-45.93M |
|
$-45.93M |
|
$-47.38M |
|
$-47.30M |
|
24.76M |
|
24.76M |
|
$-1.86 |
|
$-1.86 |
|
| Balance Sheet Financials | |
$29.89M |
|
$0.95M |
|
$2.46M |
|
$32.35M |
|
$8.42M |
|
-- |
|
$0.41M |
|
$8.83M |
|
$23.52M |
|
$23.52M |
|
$23.52M |
|
26.59M |
|
| Cash Flow Statement Financials | |
$-22.58M |
|
$-1.04M |
|
$27.61M |
|
$20.92M |
|
$24.75M |
|
$3.83M |
|
$9.91M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.55 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-94766.00% |
|
-94766.00% |
|
-94598.00% |
|
-91866.00% |
|
-91866.00% |
|
$-23.62M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
0.01 |
|
0.03M |
|
|
Return on Equity |
-195.26% |
-195.26% |
|
-141.98% |
|
-195.26% |
|
$0.88 |
|
$-0.95 |
|
$-0.91 |
|